New alternatives for the management of early Parkinson's Disease (PD): Pramipexole monotherapy in mild to moderate PD. A review of three studies

Clinical Neuropharmacology

Volumn 20, Issue SUPPL. 1, 1997, Pages

  Shannon, Kathleen M ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Dopamine agonist; Dopamine receptors; Neuropharmacology; Parkinson's disease; Pramipexole

Indexed keywords

PRAMIPEXOLE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

EID: 0031415263     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199720001-00004     Document Type: Conference Paper

References (17)

1. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-12.
2. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993;8:263-70.
3. 2 receptor agonist. Eur J Pharmacol 1992;215:161-70.
4. Lieberman A. Dopamine agonists used as monotherapy in de novo PD patients; comparisons with selegiline. Neurology 1992;42(suppl 4):37-40.
5. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S13-21.
6. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-8.
7. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S28-34.
8. 4 receptors. Eur J Pharmacol 1995;290:29-36.
9. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1989;1(suppl l):S86-94.
10. Teychenne PF, Bergsrud D, Elton RL, Racy A. Bromocriptine: long-term low-dose therapy in Parkinson's disease. Clin Neuropharmacol 1986;9:138-45.
11. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
12. Kieburtz K, for the Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA 1997;278:125-30.
13. Shannon KM, Bennett JP, Friedman JH, and the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-8.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
15. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-33.
16. 1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991;199:389-91.
17. Lees AJ, Hadad S, Shaw KM, Kohout LJ, Stern GM. Bromocriptine in parkinsonism. A long-term study. Arch Neurol 1978;35:503-5.